

PRACTICE INFORMATIO	N	REQUIRED	PHYSICIAN INFORMATION	REQUIRED
Practice Name:			Physician Name:	NPI:
Address:			Physician Name:	NPI:
City:	State:	Zip Code:	Physician Name:	NPI:

JRINARY TRACT INFECTION > RT-PCR LABORATORY REQUISITION FORM					
1 PATIENT INFORMATION	REQUIRED	2 DIAGNOSIS	(ICD-10) CODES (MEDICA	LLY NECESSARY)	REQUIRED
Bill Type: Insurance Self-Pay  ATTACH A COPY OF THE PATIENT DEMOGRAPHICS AND INSURA  COLLECTION INFO	ANCE INFORMATION REQUIRED	RSO.9 Fever, CR R53.82 Chron R68.83 Chills R30.9 Painful R39.15 Urgene R35.0 Freque R30.0 Dysuria R31.0 Gross h	unspecified ic fatigue, unspecified (without fever) I micturition, unspecified cy of urination ency of micturition ency of micturition a ematuria	R39.9 Unspecified symptotinvolving the genitourinal R21 Rash and other non seruption  Z11.51 Encounter for scree papillomavirus (HPV)  Z20.2 Exposure to disease predominantly sexually tr	oms and signs ry system pecified skin  ning of human  that is ransmitted
Collection Method  Urine  Date:  Time:  Collectors Initials:	Date/Time  AM PM	N39.0 UTI, site N30.0 Acute N30.1 Interstite N40.1 BHP wi	microscopic hematuria e not specified cystitis tial cystitis (chronic) ith lower UTI symptoms Female infertility	<ul> <li>Z11.3 Encounter for screen with a predominantly sex transmutation</li> <li>Z79.899 Other long term drug therapy</li> <li>Other:</li> </ul>	ual mode of
4 TEST ORDER				SELECT ONE OR MOR	RE (REQUIRED)
Urinalysis Reflex to Culture If you cho	ose this option pr	roceed to STEP 5 (	Patient Acknowledgeme	ent)	
Urinalysis Reflex to PCR Panel (Extend	ed Panel) <mark>If you v</mark>	want to test speci	ific pathogens select the	m below. (ABR PCR Panel ac	dd on Available)
Actinotignum schaalii Aerococcus urinae Alloscardovia omnicolens Candida albicans Candida glabrata Candida krusei (Pichia kudriavzevii) Candida parapsilosis Candida tropicalis Chlamydia trachomatis	Citrobacter freu Citrobacter kose Corynebacteriu Corynebacteriu Enterobacter ae Enterobacter cle Enterococcus fa Enterococcus fa Escherichia coli Herpes simplex	m riegelii m urealyticum erogenes oacae ecalis ecium	Herpes simplex virus 2  Klebsiella oxytoca  Klebsiella pneumoniae  Morganella morganii  Mycobacterium tubero  Mycoplasma genitalium  Mycoplasma hominis  Neisseria gonorrhoeae  Pantoea agglomerans  Proteus mirabilis	Providencia stual Pseudomonas a Serratia marceso Staphylococcus Staphylococcus Staphylococcus Staphylococcus	eruginosa cens aureus epidermis saprophyticus galactiae ginalis
Urinalysis Reflex to PCR Panel (Basic P	anel) If you want	t to test specific p	oathogens select them be	elow. (ABR PCR Panel add o	n Available)
Acinetobacter baumannii Candida albicans Candida glabrata Candida parapsilosis Candida tropicalis Citrobacter freundii	Enterobacter ad Enterobacter cl Enterococcus fa Enterococcus fa Escherichia coli Klebsiella oxyto	oacae aecalis aecium	<ul> <li>Klebsiella pneumoniae</li> <li>Morganella morganii</li> <li>Proteus mirabilis</li> <li>Proteus vulgaris</li> <li>Providencia stuartii</li> <li>Pseudomonas aerugin</li> </ul>	Staphylococcus Staphylococcus Streptococcus a	aureus saprophyticus
Sexually Transmitted Disease PCR Pan	el (STD Panel) If	you want to test s	pecific pathogens select th	nem below. (ABR PCR Panel ac	dd on Available)
Candida albicans Chlamydia trachomatis	Herpes simplex Herpes simplex		Mycoplasma genitaliui Neisseria gonorrhoeae		ginalis
Antibiotic Resistance (ABR) PCR Pane	ABR PCR Pane	el can be ordered	with the Basic or Extend	ed UTI Pathogen Panel and	STD Panel
<ul> <li>ampC, ACC, ACT/MIR (Ampicillin Resistance)</li> <li>BlaNDM-1, GES, CTX-M 1, 2, 8/25, 9, PER 1, VEE blaFOX, CMY/LAT/MOX (Extended-Spectrum Betalactamase Resistance)</li> <li>Sul 1, 2 (Sulfonamide Resistance:)</li> <li>dfrA1, 5 (Trimethoprim Resistance)</li> </ul>	<ul> <li>(Carbanpen</li> <li>Cfr (Phenico</li> <li>ermA, ermB</li> <li>tetM, tetS (T</li> </ul>	nem Resistance) ol and Lincosamide B, ermC (Macrolide F Tetracycline Resista	Resistance)	<ul> <li>Mcr-1 (Polymyxin Resist</li> <li>VanA1, VanB (Vancomyo</li> <li>mecA, mecC (femA for (Methicillin Resistance)</li> </ul>	cin Resistance) MRSA detection)
7 PATIENT ACKNOWLEDGEMENT  This specimen was provided voluntarily for analysis					REQUIRED

This specimen was provided voluntarily for analysis and I authorize AIM Laboratories to process, bill and provide results. I agree to the declarations and terms in the patient acknowledgment and irrevocable assignment of benefits on the back of this form.

Patient Signature: X Date:

Patient Name: Date of Birth:

Patient Name (Label 2):

Date of Birth:



REQUIRED

# 8 AUTHORIZED HEALTHCARE PROVIDER ACKNOWLEDGMENT

Date:

I acknowledge that documentation to support medical necessity for all tests ordered is recorded in the patient's chart. If not signed, Authorized Healthcare Provider affirms that test orders are placed in patient file with provider signature and will be available upon request. The Office of the Inspector General requires documentation in patient medical chart including date of service, tests ordered and documentation to support medical necessity.

ovider Signature:	

Patient Name (Label 1): Date of Birth:

Label 1

# DIAGNOSIS (ICD-10) CODES

The ICD-10 codes provided below are based on AMA guidelines and are for information purposes only. ICD-10 coding is the sole responsibility of the ordering provider.

### URINARY

() R50.9 Fever, unspecified

() R82.3 Hemoglobinuria

() R80.0 Isolated proteinuria

#### () A60.00 HSV of urogenital system, unspecified () A60.1 HSV infection, perianal skin/rectum () A60.9 Anogenital herpes viral infection, unspecified () A63.0 Anogenital (venereal) warts ( ) A64 Unspecified sexually transmitted disease () B00.9 Herpes viral infection, unspecified () B37.3 Candidiasis, vulva/vagina () B37.49 Candidiasis, other urogenital () B37.9 Candidiasis, unspecified () C53.9 Malignant neoplasm of cervix uteri, unspecified () Carcinoma in situ of cervix (D06.9) or vulva (D07.1) or vagina (D07.2) () D07.30 Carcinoma in situ of unspecified female genital organs () D07.39 Carcinoma in situ of other female genital organs () D07.60 Carcinoma in situ of unspecified male genital organs ( ) D07.61 Carcinoma in situ of scrotum () D07.69 Carcinoma in situ of other male genital organs () N30.00 Acute cystitis without hematuria () N30.10 Interstitial cystitis (chronic) without hematuria () N30.40 Irradiation cystitis without hematuria () N30.90 Cystitis, NOS without hematuria () N70.93 Salpingitis and oophoritis, NOS () N71.9 Inflammatory disease of uterus, NOS () N73.9 Female pelvic inflammatory disease, NOS () N72 Inflammatory disease of cervix uteri (with or without ulcer or erosion) () N76.0 Acute vaginitis () N76.1 Subacute/chronic vaginitis () Ulceration of vagina (N76.5) or vulva (N76.6) () N82.0 Vesicovaginal fistula () N82.9 Female genital tract fistula, NOS () N82.1 Other female urinary-genital tract fistulae () N82.4 Other female intestinal-genital tract fistulae () N86 Erosion, ectropion of cervix uteri () N87.9 Dysplasia of cervix uteri () N88.0 Leukoplakia of cervix uteri () N89.3 Dysplasia of vagina () N90.3 Dysplasia of vulva () N90.4 Leukoplakia of vulva () N41.0 Acute prostatitis () N41.1 Chronic prostatitis () N41.9 Inflammatory disease of prostate, unspecified () N34.1 Nonspecific urethritis () N34.3 Urethral syndrome, NOS () N39.0 Urinary tract infection, site not specified () N49.9 Inflammatory disorder of unspecified male genital organ () R10.2 Pelvic/perineal pain ( ) R30.0 Dysuria () R30.9 Painful micturiton, unspecified () R31.9 Hematuria, unspecified () R35.8 Polyuria, NOS () R36.9 Urethral discharge, unspecified () R35.0 Frequency of micturiton () R39.15 Urgency of Urination () R39.198 Other difficulties with micturition () R39.89 Other and unspecified symptoms and signs involving the urinary system () R39.9 Unspecified symptoms and signs involving the GU system

# ANTIBIOTIC RESISTANCE

() Z16.30 Resistance to unspecified antimicrobial drugs
() Z16.31 Resistance to antiparasitic drug(s)
() Z16.32 Resistance to antifungal drug(s)
() Z16.33 Resistance to antiviral drug(s)
() Z16.35 Resistance to multiple antimicrobial drugs
() Z16.39 Resistance to other specified antimicrobial drugs
() Z16.341 Resistance to single antimycobacterial drug
() Z16.342 Resistance to multiple antimycobacterial drugs

#### PATIENT ACKNOWLEDGMENT AND IRREVOCABLE ASSIGNMENT OF BENEFITS

() Atypical squamous cells of undetermined significance (ASCUS), cytologic smear of cervix (R87.610) or vagina

() ASC-US, can't exclude high grade squamous intraepithelial lesion (ASC-H), cervix (R87.611) or vagina (R87.621)

() Low grade squamous intraepithelial lesion (LGSIL), cytologic smear of cervix (R87.612) or vagina (R87.622)

() High grade squamous intraepithelial lesion (HGSIL), cytologic smear of cervix (R87.613) or vagina (R87.623)

() R82.90 Other unspecified abnormal findings in urine (positive nitrite or leukocyte esterase)

() Cytologic evidence malignancy, cervix (R87.614) or vagina (R87.624)

() R87.810 Cervical high risk human papillomavirus (HPV) DNA test positive

() R87.811 Vaginal high risk human papillomavirus (HPV) DNA test positive

The information provided on this form and on the label affixed to the specimen cup is accurate. The specimen identified on this form is my own. I have not adulterated it in any way. I am voluntarily submitting this specimen for analysis by my healthcare provider and/or third party lab. I authorize the lab to release the results of this test to the ordering healthcare provider. The lab is authorized to bill my insurance provider, or any payer, whether fully insured or self-insured, and I will irrevocably assign any payment of benefits, claims, rights, and interests related to the services my healthcare provider performed against any payer. I further authorize the lab and my healthcare provider to release to my insurance provider any medical information necessary to process this claim.

I acknowledge that AIM Laboratories may be an out-of-network facility/provider with my insurance provider. I am also aware that in some circumstances my insurance provider may send the payment directly to me. I agree to endorse the insurance check and forward it to AIM Laboratories within 15 days of receipt as payment towards the lab services provided by AIM. I acknowledge that I am responsible for any amounts =not covered by my insurer including any deductibles and co-payments/co-insurance. I understand that AIM Laboratories may use my specimen and any testing performed on that specimen for research and development so long as the information has been de-identified pursuant to law. I am aware that all AIM Laboratories Privacy Practices can be found at www.aimlaboratories.com.